The Epigenetic Rescue of Dystrophin Dysfunction Study of Givinostat in Ambulatory Duchenne Muscular Dystrophy Patients
Overview
Overview
Authors
Affiliations
Affiliations
Soon will be listed here.
References
1.
Mozzetta C, Sartorelli V, Steinkuhler C, Puri P
. HDAC inhibitors as pharmacological treatment for Duchenne muscular dystrophy: a discovery journey from bench to patients. Trends Mol Med. 2024; 30(3):278-294.
PMC: 11095976.
DOI: 10.1016/j.molmed.2024.01.007.
View
2.
Mercuri E, Vilchez J, Boespflug-Tanguy O, Zaidman C, Mah J, Goemans N
. Safety and efficacy of givinostat in boys with Duchenne muscular dystrophy (EPIDYS): a multicentre, randomised, double-blind, placebo-controlled, phase 3 trial. Lancet Neurol. 2024; 23(4):393-403.
DOI: 10.1016/S1474-4422(24)00036-X.
View
3.
Mazzone E, Coratti G, Sormani M, Messina S, Pane M, DAmico A
. Timed Rise from Floor as a Predictor of Disease Progression in Duchenne Muscular Dystrophy: An Observational Study. PLoS One. 2016; 11(3):e0151445.
PMC: 4794120.
DOI: 10.1371/journal.pone.0151445.
View
4.
Zambon A, Ayyar Gupta V, Ridout D, Manzur A, Baranello G, Trucco F
. Peak functional ability and age at loss of ambulation in Duchenne muscular dystrophy. Dev Med Child Neurol. 2022; 64(8):979-988.
PMC: 9303180.
DOI: 10.1111/dmcn.15176.
View
5.
Bettica P, Petrini S, DOria V, DAmico A, Catteruccia M, Pane M
. Histological effects of givinostat in boys with Duchenne muscular dystrophy. Neuromuscul Disord. 2016; 26(10):643-649.
DOI: 10.1016/j.nmd.2016.07.002.
View